OPKO Health to sell BioReference lab business to LabCorp for $722 million
OPKO Health and its subsidiary BioReference Health agreed on October 14, 2026, to sell certain assets of BioReference's clinical and anatomic pathology testing business to Laboratory Corporation of America Holdings. The buyer would pay $722 million in cash at closing, plus up to $150 million more over up to ten years based on sales of the 4Kscore prostate cancer test. Closing depends on customary conditions, including HSR antitrust clearance, and is not subject to a financing condition.
Key points
- Cash purchase price of $722 million at closing, subject to adjustments based on Business revenues at closing
- Up to $150 million in additional cash over up to ten years, based on revenue from sales of the 4Kscore test by the buyer
- Closing requires HSR antitrust clearance; either party may terminate if the deal has not closed by April 14, 2027, which may be extended by mutual agreement
- Buyer would pay OPKO a termination fee of $28,880,000 if the deal ends due to failure to obtain HSR clearance or other required approvals
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.